Skip to main content

Norditropin Disease Interactions

There are 9 disease interactions with Norditropin (somatropin).

Major

Human growth hormone (applies to Norditropin) active malignancy

Major Potential Hazard, Moderate plausibility. Applicable conditions: Brain/Intracranial Tumor, Breast Cancer, Lung Cancer, Prostate Cancer, Bladder Cancer, Skin Cancer

Somatropin and somatrogon are contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin and somatrogon should be discontinued if there is any evidence of recurrence.

Switch to professional interaction data

Major

Human growth hormone (applies to Norditropin) acute critical illness

Major Potential Hazard, Moderate plausibility. Applicable conditions: Acute (Surgical) Abdomen, Pulmonary Impairment, Sepsis

Treatment with somatropin and somatrogon is contraindicated in patients with acute critical illness due to any complications following open heart surgery, abdominal surgery, multiple trauma, or acute respiratory failure. Patients with these conditions have an increased risk of mortality.

Switch to professional interaction data

Major

Human growth hormone (applies to Norditropin) diabetic retinopathy

Major Potential Hazard, High plausibility.

Somatropin and somatrogon is contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy.

Switch to professional interaction data

Major

Human growth hormone (applies to Norditropin) Prader-Willi Syndrome

Major Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment, Sleep Apnea, Obesity

Somatropin and somatrogon is contraindicated in patients with Prader-Willi Syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients.

Switch to professional interaction data

Moderate

Growth hormone (applies to Norditropin) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

The use of growth hormone has been associated with resistance to insulin. Patients with diabetes mellitus or impaired glucose tolerance should be observed closely during therapy. The dose of antihyperglycemic drugs (insulin or oral/injectable agents) may require adjustment.

Switch to professional interaction data

Moderate

Growth hormone (applies to Norditropin) hypothyroidism

Moderate Potential Hazard, Moderate plausibility.

The use of growth hormone has been associated with the development of hypothyroidism. Patients should be monitored baseline and periodically for adequate thyroid function. Inadequate treatment of hypothyroidism may inhibit the optimal response to growth hormone.

Switch to professional interaction data

Moderate

Human growth hormone (applies to Norditropin) intracranial hypertension

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Papilledema Associated with Increased Intracranial Pressure

Intracranial hypertension with papilledema, visual changes, nausea and/or vomiting has been reported in a small number of patients treated with somatropin and somatrogon. Fundoscopic examination should be performed before treatment initiation to exclude preexisting papilledema, and should be continued periodically during treatment. If papilledema is observed during treatment, therapy should be stopped. Treatment could be restarted at a lower dose once intracranial hypertension has been resolved. Patients with Turner Syndrome might be at increased risk of developing intracranial hypertension.

Switch to professional interaction data

Moderate

Human growth hormone (applies to Norditropin) scoliosis

Moderate Potential Hazard, Moderate plausibility.

Progression of scoliosis can occur in patients who experience rapid growth. Since somatropin and somatrogon increase growth rate, children with a history of scoliosis should be monitored for progression of this condition. Physicians should be alert for this skeletal abnormality which can be commonly seen in patients with Turner and Prader-Willi syndromes, and can manifest during somatropin and somatrogon treatment.

Switch to professional interaction data

Moderate

Somatropin (applies to Norditropin) Turner syndrome

Moderate Potential Hazard, Moderate plausibility.

Somatropin may increase the risk of otitis media in patients with Turner syndrome. These patients should be evaluated carefully for otitis media and other ear disorders as they have an increased risk of ear and hearing disorders.

Switch to professional interaction data

Norditropin drug interactions

There are 436 drug interactions with Norditropin (somatropin).

Norditropin alcohol/food interactions

There is 1 alcohol/food interaction with Norditropin (somatropin).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer